Efficacy of drug treatments for generalised anxiety disorder: Systematic review and meta-analysis

BMJ

Volumn 342, Issue 7798, 2011, Pages 637-

  Baldwin, David ^a   Woods, Robert ^b   Lawson, Richard ^b   Taylor, David ^c  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b Complete Medical Group ^*  (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DULOXETINE; ESCITALOPRAM; FLUOXETINE; LORAZEPAM; PAROXETINE; PLACEBO; PREGABALIN; SERTRALINE; TIAGABINE; VENLAFAXINE;

DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; GENERALIZED ANXIETY DISORDER; HAMILTON ANXIETY SCALE; HUMAN; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; HUMANS; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79952795159     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.d1199     Document Type: Review

References (68)

1. Allgulander C. Generalized anxiety disorder: what are we missing? Eur Neuropsychopharmacol 2006;16:S101-8.
2. Hoffman DL, Dukes EM, Wittchen H-U. Human and economic burden of generalized anxiety disorder. Depress Anxiety 2008;25:72-90. (Pubitemid 351213928)
3. Wittchen H-U, Kessler RC, Beesdo K, Krause P, Höfler M, Hoyer J. Generalized anxiety and depression in primary care: prevalence, recognition, and management. J Clin Psychiatry 2002;63(suppl 8):24-34. (Pubitemid 34535254)
4. Maier W, Gänsicke M, Freyberger HJ, Linz M, Heun R, Lecrubier Y. Generalized anxiety disorder (ICD-10) in primary care from a crosscultural perspective: a valid diagnostic entity? Acta Psychiatr Scand 2000;101:29-36.
5. Baldwin DS, Waldman S, Allgulander C. Evidence-based pharmacotherapy of generalized anxiety disorder. Int J Neuropsychopharmacol 2011;Jan7:1-14. epub ahead of print.
6. Bandelow B, Zohar J, Hollander E, Kasper S, Möller HJ, WFSBP Task Force on Treatment Guidelines for Anxiety O-CaP-TSD. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J Biol Psychiatry 2008;9:248-312.
7. National Institute for Health and Clinical Excellence. NICE clinical guidance 22 (amended). Anxiety (amended). Management of anxiety (panic disorder, with or without agoraphobia, and generalised anxiety disorder) in adults in primary, secondary and community care. April 2007. www.nice.org.uk/nicemedia/ pdf/CG022NICEguidelineamended.pdf.
8. Martin JLR, Sainz-Pardo M, Furukawa TA, Martin-Sanchez E, Seoane T, Galan C. Review: benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials. J Psychopharmacol 2007;21:774-82. (Pubitemid 47437920)
9. Schmitt R, Gazalle FK, de Lima MS, Cunha A, Souza J, Kapczinski F. The efficacy of antidepressants for generalized anxiety disorder: a systematic review and meta-analysis. Rev Bras Psiquiatr 2005;27:18-24. (Pubitemid 40477449)
10. Mitte K, Noack P, Steil R, Hautzinger M. Ameta-analytic review of the efficacy of drug treatment in generalized anxiety disorder. J Clin Psychopharmacol 2005;25:141-50. (Pubitemid 40395092)
11. Salanti G, Higgins JPT, Ades AE, Ioannidis JPA. Evaluation of networks of randomized trials. Stat Methods Med Res 2008;17:279-301.
12. Datastar. Dialog DataStar. 2009. www.datastarweb.com/.
13. Cochrane Collaboration. UK Cochrane Centre. 2009. http://cochrane.co.uk/ en/index.html.
14. Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS-a Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput 2000;10:325-37.
15. Caldwell DM, Ades AE, Higgins JPT. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 2005;331:897-900. (Pubitemid 41502718)
16. Sutton AJ, Abrams KR. Bayesian methods in meta-analysis and evidence synthesis. Stat Methods Med Res 2001;10:277-303.
17. Nicolini H, Bakish D, Duenas H, Spann M, Erickson J, Hallberg C, et al. Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial. Psychol Med 2009;39:267-76.
18. Pollack MH, Tiller J, Xie F, Trivedi MH. Tiagabine in adult patients with generalized anxiety disorder: results from 3 randomized, double-blind, placebo-controlled, parallel-group studies. J Clin Psychopharmacol 2008;28:308-16.
19. Rynn M, Russell J, Erickson J, Detke MJ, Ball S, Dinkel J, et al. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depress Anxiety 2008;25:182-9. (Pubitemid 351499896)
20. Brawman-Mintzer O, Knapp RG, Rynn M, Carter RE, Rickels K. Sertraline treatment for generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2006;67:874-81. (Pubitemid 44049085)
21. Montgomery SA, Tobias K, Zornberg GL, Kasper S, Pande AC. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week,multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry 2006;67:771-82. (Pubitemid 43946184)
22. Wan GJ, Zhang HF, Tedeschi MA, Hackett D. Estimation of symptom-free days in generalized anxiety disorder. Curr Med Res Opin 2006;22:587-91.
23. Pollack MH, Roy-Byrne PP, Van Ameringen M, Snyder H, Brown C, Ondrasik J, et al. The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: results of a placebo-controlled study. J Clin Psychiatry 2005;66:1401-8. (Pubitemid 41779538)
24. Rickels K, Pollack MH, Feltner DE, Lydiard RB, Zimbroff DL, Bielski RJ, et al. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry 2005;62:1022-30. (Pubitemid 41248382)
25. Bielski RJ, Bose A, Chang C-C. A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann Clin Psychiatry 2005;17:65-9. (Pubitemid 40967128)
26. Ball SG, Kuhn A, Wall D, Shekhar A, Goddard AW. Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a double-blind, prospective comparison between paroxetine and sertraline. J Clin Psychiatry 2005;66:94-9.
27. Steiner M, Allgulander C, Ravindran A, Kosar H, Burt T, Austin C. Gender differences in clinical presentation and response to sertraline treatment of generalized anxiety disorder. Hum Psychopharmacol Clin Exp 2005;20:3-13. (Pubitemid 40227640)
28. Nimatoudis I, Zissis NP, Kogeorgos J, Theodoropoulou S, Vidalis A, Kaprinis G. Remission rates with venlafaxine extended release in Greek outpatients with generalized anxiety disorder. A double-blind, randomized, placebo controlled study. Int Clin Psychopharmacol 2004;19:331-6.
29. Lenox-Smith AJ, Reynolds A. A double-blind, randomised, placebo controlled study of venlafaxine XL in patients with generalised anxiety disorder in primary care. Br J Gen Pract 2003;53:772-7. (Pubitemid 37254121)
30. Feltner DE, Crockatt JG, Dubovsky SJ, Cohn CK, Shrivastava RK, Targum SD, et al. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol 2003;23:240-9. (Pubitemid 36807791)
31. Rickels K, Zaninelli R, McCafferty J, Bellew K, Iyengar M, Sheehan D. Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. Am J Psychiatry 2003;160:749-56. (Pubitemid 41079609)
32. Pande AC, Crockatt JG, Feltner DE, Janney CA, Smith WT, Weisler R, et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry 2003;160:533-40. (Pubitemid 41094262)
33. Silverstone PH, Salinas E. Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder. J Clin Psychiatry 2001;62:523-9. (Pubitemid 32703091)
34. Pollack MH, Zaninelli R, Goddard A, McCafferty JP, Bellew KM, Burnham DB, et al. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry 2001;62:350-7. (Pubitemid 32545557)
35. Davidson JRT, DuPont RL, Hedges D, Haskins JT. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry 1999;60:528-35. (Pubitemid 29413473)
36. Hartford JT, Endicott J, Kornstein SG, Allgulander C, Wohlreich MM, Russell JM, et al. Implications of pain in generalized anxiety disorder: efficacy of duloxetine. Prim Care Companion J Clin Psychiatry 2008;10:197-204. (Pubitemid 351879954)
37. Koponen H, Allgulander C, Erickson J, Dunayevich E, Pritchett Y, Detke MJ, et al. Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians. Prim Care Companion J Clin Psychiatry 2007;9:100-7. (Pubitemid 46607463)
38. Hartford J, Kornstein S, Liebowitz M, Pigott T, Russell J, Detke M, et al. Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial. Int Clin Psychopharmacol 2007;22:167-74. (Pubitemid 46559873)
39. Davidson JRT, Bose A, Korotzer A, Zheng H. Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Depress Anxiety 2004;19:234-40. (Pubitemid 39014143)
40. Baldwin DS, Huusom AKT, Mæhlum E. Escitalopram and paroxetine in the treatment of generalised anxiety disorder. Br J Psychiatry 2006;189:264-72.
41. Data on file, H. Lundbeck A/S. Flexible dose comparison of the safety and efficacy of Lu 26-054 (escitalopram) and placebo in the treatment of generalised anxiety disorder. 2005;SCT-MD-05.
42. Data on file, H. Lundbeck A/S. Flexible-dose comparison of the safety and efficacy of escitalopram and placebo in the treatment of generalised anxiety disorder. 2005;SCT-MD-06.
43. Montgomery S, Chatamra K, Pauer L, Whalen E, Baldinetti F. Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder. Br J Psychiatry 2008;193:389-94.
44. Adams JB, Pyke RE, Costa J, Cutler NR, Schweizer E, Wilcox CS, et al. A double-blind, placebo-controlled study of a CCK-B receptor antagonist, CI-988, in patients with generalized anxiety disorder. J Clin Psychopharmacol 1995;15:428-34. (Pubitemid 26005593)
45. Bourin M, Malinge M. Controlled comparison of the effects and abrupt discontinuation of buspirone and lorazepam. Prog Neuro- Psychopharmacol Biol Psychiat 1995;19:567-75.
46. 1A agonist, buspirone hydrochloride, in migraineurs with anxiety: a randomized, prospective, parallel group, double-blind, placebo-controlled study. Headache 2005;45:1004-11.
47. Sramek JJ, Tansman M, Suri A, Hornig-Rohan M, Amsterdam JD, Stahl SM, et al. Efficacy of buspirone in generalized anxiety disorder with coexisting mild depressive symptoms. J Clin Psychiatry 1996;57:287-91. (Pubitemid 26251107)
48. Aliyev NA, Aliyev ZN. Valproate (depakine-chrono) in the acute treatment of outpatients with generalized anxiety disorder without psychiatric comorbidity: randomized, double-blind placebo-controlled study. Eur Psychiatry 2008;23:109-14. (Pubitemid 351284508)
49. Andreatini R, Sartori VA, Seabra MLV, Leite JR. Effect of valepotriates (valerian extract) in generalized anxiety disorder: a randomized placebo-controlled pilot study. Phytother Res 2002;16:650-4. (Pubitemid 35334186)
50. Ansseau M, Olié J-P, von Frenckell R, Jourdain G, Stehle B, Guillet P. Controlled comparison of the efficacy and safety of four doses of suriclone, diazepam, and placebo in generalized anxiety disorder. Psychopharmacology (Berl) 1991;104:439-43.
51. Boerner RJ, Sommer H, Berger W, Kuhn U, Schmidt U, Mannel M. Kava-Kava extract LI 150 is as effective as opipramol and buspirone in generalised anxiety disorder - an 8-week randomized, doubleblind multi-centre clinical trial in 129 out-patients. Phytomedicine 2003;10(suppl 4):38-49. (Pubitemid 36597155)
52. Brawman-Mintzer O, Knapp RG, Nietert PJ. Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study. J Clin Psychiatry 2005;66:1321-5. (Pubitemid 41546513)
53. Bystritsky A, Kerwin L, Feusner JD, Vapnik T. A pilot controlled trial of bupropion XL versus escitalopram in generalized anxiety disorder. Psychopharmacol Bull 2008;41:46-51.
54. Dunayevich E, Erickson J, Levine L, Landbloom R, Schoepp DD, Tollefson GD. Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder. Neuropsychopharmacology 2008;33:1603-10. (Pubitemid 351684700)
55. Linden M, Hadler D, Hofmann S. Randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a new isoindoline derivative (DN-2327) in generalized anxiety. Hum Psychopharmacol 1997;12:445-52. (Pubitemid 27462820)
56. Llorca P-M, Spadone C, Sol O, Danniau A, Bougerol T, Corruble E, et al. Efficacy and safety of hydroxyzine in the treatment of generalized anxiety disorder: a 3-month double-blind study. J Clin Psychiatry 2002;63:1020-7. (Pubitemid 35388062)
57. Naukkarinen H, Raassina R, Penttinen J, Ahokas A, Jokinen R, Koponen H, et al. Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study. Eur Neuropsychopharmacol 2005;15:617-23. (Pubitemid 41587412)
58. Pollack MH, Simon NM, Zalta AK, Worthington JJ, Hoge EA, Mick E, et al. Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biol Psychiatry 2006;59:211-5. (Pubitemid 43208966)
59. Simon NM, Connor KM, LeBeau RT, Hoge EA, Worthington JJ III, Zhang W, et al. Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings. Psychopharmacology (Berl) 2008;197:675-81.
60. Stein DJ, Ahokas AA, de Bodinat C. Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2008;28:561-6.
61. Cochrane Collaboration. Cochrane handbook for systematic reviews of interventions. 2009. www.cochrane-handbook.org/.
62. General Medical Council. Good practice in prescribing medicines. 2008. www.gmc-uk.org/guidance/current/library/prescriptions-faqs.asp#5c.
63. Piercy MA, Sramek JJ, Kurtz NM, Cutler NR. Placebo response in anxiety disorders. Ann Pharmacother 1996;30:1013-9. (Pubitemid 26295256)
64. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JPT, Churchill R, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009;373:746-58.
65. Pollack MH. Optimizing pharmacotherapy of generalized anxiety disorder to achieve remission. J Clin Psychiatry 2001;62(suppl 19):20-5. (Pubitemid 32911036)
66. Mandos LA, Reinhold JA, Rickels K. Achieving remission in generalized anxiety disorder. What are the treatment options? 2009. www.psychiatrictimes. com/display/article/10168/1370513.
67. National Institute for Health and Clinical Excellence. Generalised anxiety disorder and panic disorder (with or without agoraphobia) in adults: management in primary, secondary and community care. NICE clinical guideline 113, January 2011. www.nice.org.uk/nicemedia/live/12147/51542/51542.pdf.
68. Hoffman EJ, Mathew SJ. Anxiety disorders: a comprehensive review of pharmacotherapies. Mt Sinai J Med 2008;75:248-62.